ArticleInternational journal of molecular sciences2020
Induction of Antitumor Immunity by Exosomes Isolated from Cryopreserved Cord Blood Monocyte-Derived Dendritic Cells.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Current understanding and new promises of umbilical cord blood in emerging clinical applications.Science China. Life sciences · 2026Review
- Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.Investigational new drugs · 2026Review
- Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.The Prostate · 2025Article
- The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.Molecular biotechnology · 2025Review
- Application of Cord Blood-Derived Exosomes in Tumor Prevention and Treatment.Clinical Medicine Insights. Oncology · 2025Review
- Landscape of exosomes to modified exosomes: a state of the art in cancer therapy.RSC advances · 2024Review
- Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.Cancer communications (London, England) · 2024Review
- Recent advances to address challenges in extracellular vesicle-based applications for lung cancer.Acta pharmaceutica Sinica. B · 2024Review
- From bench to bedside: The promising value of exosomes in precision medicine for CNS tumors.Heliyon · 2024Review
- Therapeutic cancer vaccines: advancements, challenges, and prospects.Signal transduction and targeted therapy · 2023Review
- The therapeutic potential of exosomes in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- Landscape of tumor and immune system cells-derived exosomes in lung cancer: mediators of antitumor immunity regulation.Frontiers in immunology · 2023Review
- Phospholipid-Membrane-Based Nanovesicles Acting as Vaccines for Tumor Immunotherapy: Classification, Mechanisms and Applications.Pharmaceutics · 2022Review
- Exosomes in Cancer Diagnosis and Therapy.International journal of molecular sciences · 2022Article
- Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies.Cells · 2022Review
- Exosomes as Drug Carriers in Anti-Cancer Therapy.Frontiers in cell and developmental biology · 2022Review
- Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.Drug delivery · 2021Review
- Cord-Blood-Derived Professional Antigen-Presenting Cells: Functions and Applications in Current and Prospective Cell Therapies.International journal of molecular sciences · 2021Review
- Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
(1) Background: Dendritic cell (DC) vaccination has shown outstanding achievements in cancer treatment, although it still has some adverse side effects. Vaccination with DC-derived exosomes has been thought to overcome the side effects of the parental DCs. (2) Method: We performed the experiments to check the ability of cryopreserved umbilical cord blood mononuclear cell-derived DCs (cryo CBMDCs) and their exosomes to prime allogeneic T cell proliferation and allogeneic peripheral blood mononuclear cell (alloPBMCs) cytotoxicity against A549 lung cancer cells. (3) Results: We found that both lung tumor cell lysate-pulsed DCs and their exosomes could induce allogeneic T cell proliferation. Moreover, alloPBMCs primed with tumor cell lysate-pulsed DCs and their exosomes have a greater cytotoxic activity against A549 cells compared to unprimed cells and cells primed with unpulsed DCs and their exosomes. (4) Conclusion: Tumor cell lysate-pulsed DCs and their exosomes should be considered to develop into a novel immunotherapeutic strategy-e.g., vaccines-for patients with lung cancer. Our results also suggested that cryo umbilical cord blood mononuclear cells source, which is a readily and available source, is effective for generation of allogeneic DCs and their exosomes will be material for vaccinating against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.